Can Sertraline Cause Seizures in People With Epilepsy?

Sertraline carries a low but real risk of seizures, roughly comparable to that of most other SSRIs and substantially lower than the risk posed by older antidepressants or bupropion. A large analysis of the FDA’s adverse-event database placed sertraline’s seizure-reporting odds among the lowest of commonly prescribed antidepressants. Still, “low risk” is not “no risk,” and the picture gets more complicated for people who already have epilepsy, take interacting medications, or are pregnant.

How Sertraline’s Seizure Risk Stacks Up Against Other Antidepressants

Not all antidepressants are created equal when it comes to seizure risk. A study mining the FDA Adverse Event Reporting System ranked common antidepressants by their reporting odds ratio for seizures. Bupropion topped the list with the highest signal, followed by the older tricyclics amitriptyline and imipramine. Sertraline landed near the bottom of the ranking, with a reporting odds ratio of about 2.0, lower than escitalopram, fluoxetine, citalopram, and duloxetine. Only vortioxetine and paroxetine had lower seizure-reporting signals among the drugs studied.¹

That does not mean sertraline causes seizures twice as often as a drug with a ratio of 1.0. Reporting-odds ratios from adverse-event databases reflect how often a side effect gets reported relative to other drugs in the database, not the actual rate at which it happens in the population. They are best used for comparing drugs to each other rather than for quoting absolute risk numbers. What the data do tell you is that if your doctor is choosing an antidepressant and seizure risk is a concern, sertraline sits comfortably in the lower-risk tier alongside paroxetine and vortioxetine, well below bupropion and the tricyclics.

Taking Sertraline When You Already Have Epilepsy

Depression is extremely common in people with epilepsy, and for years many doctors were cautious about prescribing antidepressants to this group, worried about pushing seizure frequency up. The evidence on sertraline in epilepsy turns out to be mostly reassuring, with some caveats worth knowing.

A randomized clinical trial assigned people with epilepsy and depression to either sertraline or cognitive behavioral therapy. The study found no meaningful difference in seizure occurrence between the two groups. Generalized tonic-clonic seizures occurred at nearly identical rates whether people were on sertraline or receiving therapy alone, and the researchers concluded that serotonin reuptake inhibition does not appear to increase seizures in people with epilepsy.²

An earlier observational study painted a slightly more nuanced picture. Among 100 patients with epilepsy who started sertraline, six experienced an increase in seizure frequency. Interestingly, those six patients were on lower sertraline doses than the rest of the group. In five of the six cases, adjusting antiepileptic drug doses brought seizure frequency back to baseline, and four of those five stayed on sertraline at the same dose.³ The fact that those who worsened were on lower, not higher, doses complicates the intuitive assumption that more drug means more risk. It may reflect individual sensitivity or underlying seizure instability rather than a simple dose-dependent effect of sertraline.

Taken together, these studies suggest that sertraline is a reasonable option for treating depression in people with epilepsy, but close monitoring of seizure frequency early on is smart, especially during the first weeks of treatment.

Children and Adolescents With Epilepsy

Depression in young people with epilepsy is underdiagnosed and undertreated, partly because of that same worry about antidepressants worsening seizures. A study of children and adolescents with both epilepsy and a depressive disorder found that sertraline and fluoxetine were generally safe in this group. All patients saw improvement in their depressive symptoms. Seizures worsened in only two patients out of thirty-six. Side effects were mild: one child on sertraline had gastrointestinal problems that resolved when the medication was switched, and one on fluoxetine developed a rash that cleared after switching to sertraline.⁴

The sample was small, so the findings should be taken as encouraging rather than definitive. But they matter because untreated depression in young people with epilepsy is itself a serious medical concern. It worsens quality of life, interferes with medication adherence, and is linked to higher suicide risk. The evidence here supports cautious use of SSRIs like sertraline when a child or adolescent with epilepsy needs treatment for depression.

Indirect Pathways to Seizures

Sertraline does not have to act directly on seizure thresholds to cause a seizure. There are at least two indirect mechanisms that can bridge the gap between taking the drug and having a convulsion, and understanding them matters because they are largely preventable.

Hyponatremia From SIADH

SSRIs, including sertraline, can occasionally trigger a condition where the body retains too much water relative to sodium. When sodium levels in the blood drop severely, the brain swells, and seizures can follow. A case report documented this pathway in a patient on sertraline whose sodium fell to dangerously low levels, triggering life-threatening neurological complications. Sodium levels below about 120 milliequivalents per liter can lead to seizures, coma, and even death.⁵

This complication is rare but more common in older adults, people who take diuretics, and those who drink large amounts of water. Symptoms of low sodium creep up gradually: confusion, nausea, headache, and unsteadiness. If you are on sertraline and notice these symptoms, especially within the first few weeks, it is worth getting your sodium level checked. Catching it early means the fix is usually straightforward: fluid restriction and, in some cases, stopping or changing the medication.

Serotonin Syndrome

Combining sertraline with other drugs that boost serotonin, like certain migraine medications, tramadol, or MAO inhibitors, can push serotonin levels high enough to cause a dangerous reaction. Serotonin syndrome typically involves muscle twitching, rapid heart rate, sweating, agitation, and confusion. In severe cases, seizures can occur along with organ failure.⁶ Serotonin syndrome is almost always the result of drug combinations rather than sertraline alone, so the practical takeaway is to make sure every prescriber you see knows everything you are taking.

Drug Interactions and How Your Body Processes Sertraline

How quickly your body breaks down sertraline depends on liver enzymes, particularly CYP2D6 and CYP2C19. If another medication you take inhibits those enzymes, sertraline can build up to higher-than-expected levels in your blood, potentially increasing side effects including the risk of seizures or involuntary muscle jerking (myoclonus).

A study looking at antidepressant-related seizures and myoclonus tested whether genetic differences in these enzymes were behind the events. None of the patients tested turned out to be genetic poor metabolizers. However, nearly half were taking other drugs that inhibit CYP2D6, such as certain antipsychotic medications, effectively converting them into poor metabolizers regardless of their genetics.⁷

This finding highlights that the problem is often not the antidepressant itself but the cocktail of medications a person is taking. If you are prescribed sertraline alongside an antipsychotic, a certain antihistamine, or another drug that slows liver metabolism, your doctor may need to adjust doses accordingly. Pharmacists are often the best safety net here, as they screen for these interactions automatically when filling prescriptions.

Animal Research Suggesting Sertraline May Protect Against Seizures

One of the more counterintuitive findings in this area comes from animal studies. In rodent models of seizures, sertraline did not just fail to worsen seizures; it actually prevented them. A single injection at a moderate dose blocked both the behavioral and brain-wave changes associated with chemically induced seizures. Even at a lower dose that had no effect as a single injection, repeated daily administration for a week was enough to suppress seizure activity.⁸

These results align with a broader body of preclinical research suggesting that boosting serotonin in the brain may raise the seizure threshold. Serotonin appears to have an inhibitory effect on seizure-generating circuits, which is one reason researchers have speculated that SSRIs might eventually find a role as adjunctive treatments in epilepsy. Human data have not yet confirmed this anti-seizure effect directly, but the animal evidence helps explain why sertraline so rarely worsens seizures in clinical studies and may even partly explain the reassuring clinical trial results in epilepsy populations.

Sertraline for Psychogenic Nonepileptic Seizures

Not all seizures are epileptic. Psychogenic nonepileptic seizures look like epileptic seizures but do not involve the abnormal electrical discharges in the brain that define epilepsy. They are driven by psychological processes and are often associated with trauma, anxiety, and depression. This is a condition where sertraline has been studied not as a risk factor but as a potential treatment.

A pilot trial found that patients assigned to sertraline experienced a 45% reduction in seizure rates from baseline, a statistically significant improvement, while the placebo group saw an 8% increase.⁹ A larger multicenter trial tested sertraline alone, cognitive behavioral therapy alone, and the combination. Patients receiving therapy with sertraline had about a 59% reduction in monthly seizures, while sertraline alone produced a smaller, non-significant reduction of about 27%.¹⁰

The takeaway from these studies is that sertraline can be part of the treatment strategy for psychogenic nonepileptic seizures, particularly when combined with therapy. It is worth noting that this is a condition frequently misdiagnosed as epilepsy, meaning some people who believe sertraline “caused” a seizure may actually have psychogenic events that the medication was not responsible for and might even help treat.

Prenatal Sertraline and Seizures in Newborns

Pregnant women who take SSRIs, including sertraline, sometimes worry about the effect on their baby. A systematic review of nine studies found that neonatal seizures occurred in about 0.3% to 0.9% of babies exposed to antidepressants in the womb, compared with 0.1% to 0.3% in unexposed babies. SSRI use was associated with up to a fivefold increase in the risk of neonatal seizures, and exposure during the third trimester appeared to carry more risk than earlier exposure.¹¹

Before that statistic causes alarm, context matters enormously. A large population-based study examined the same question while accounting for the many ways women who take antidepressants during pregnancy differ from women who do not: they are more likely to have depression (obviously), other mental health conditions, different socioeconomic profiles, and other pregnancy complications. After adjusting for these factors, the elevated neonatal seizure risk was almost entirely explained by differences between the groups rather than by the medication itself.¹²

In absolute terms, the difference was tiny: about 0.17% of exposed children had neonatal seizures versus 0.12% of unexposed children. When confounders were accounted for, even that small gap shrank. This does not mean the question is fully settled, but it does mean that the crude risk numbers vastly overstate any causal link. For women who need sertraline to manage serious depression during pregnancy, the risk of untreated maternal depression to both mother and baby is well established and likely outweighs the very small and possibly non-causal increase in neonatal seizure risk.

What Happens When You Stop Sertraline

Discontinuing sertraline abruptly can produce a withdrawal syndrome that includes dizziness, irritability, “brain zaps” (a sensation of electrical jolts in the head), and in rare cases neurological symptoms that can resemble or be mistaken for seizure activity. An analysis of withdrawal reactions reported to the World Health Organization’s monitoring system found that sertraline’s withdrawal profile leaned more heavily toward central nervous system symptoms compared with psychiatric symptoms. This pattern was similar to paroxetine’s but different from fluoxetine’s, likely because fluoxetine has a much longer half-life and leaves the body more gradually.¹³

True epileptic seizures from SSRI withdrawal are extremely rare and poorly documented, but sudden discontinuation can produce symptoms that feel seizure-like. The practical advice is straightforward: taper sertraline gradually under medical supervision rather than stopping cold. Most prescribers will step the dose down over a few weeks, which dramatically reduces the intensity of withdrawal symptoms.

EEG Changes and Brain Activity on Sertraline

Quantitative EEG studies have shown that sertraline does alter brain electrical activity in a dose-dependent way. At standard therapeutic doses around 100 milligrams, the changes are slight and resemble patterns associated with mild improvements in alertness. At higher doses of 200 to 400 milligrams, the EEG shifts become more pronounced and start to look like the patterns seen with older tricyclic antidepressants, suggesting a qualitatively different kind of brain-state change at the higher end of the dosing range.¹⁴

This does not mean high-dose sertraline causes seizures, but it does suggest that the drug’s effect on brain electrical activity is not simply a flat line at any dose. For people at elevated seizure risk, this is one more reason to start at a low dose and increase slowly, giving the brain time to adjust to each step. It also reinforces why staying within the recommended dosage range matters and why accidental overdose carries more neurological risk than therapeutic use.

When to Be Concerned and When Not to Be

If you are taking sertraline at a normal dose, have no history of epilepsy, are not combining it with drugs that boost serotonin or inhibit its metabolism, and your kidney and liver function are normal, the odds of sertraline causing a seizure are vanishingly small. The situations that genuinely elevate risk are fairly specific:

Pre-existing epilepsy: Risk is still low, but monitoring during the first weeks is sensible.
Drug combinations: Other serotonergic drugs, CYP2D6 inhibitors, or medications that lower the seizure threshold independently all change the calculus.
Sodium imbalance: Older adults, people on diuretics, or those with conditions that affect fluid balance face a higher risk of SSRI-induced low sodium, which can trigger seizures indirectly.
Abrupt discontinuation: Stopping without tapering can produce neurological withdrawal symptoms, though true seizures from withdrawal are exceedingly rare.
Overdose: In acute overdose, the seizure risk rises, as it does with most centrally acting medications. This is a toxicology concern rather than a therapeutic one.

For the vast majority of people prescribed sertraline, seizures are not a realistic worry. The drug ranks among the lower-risk antidepressants for this side effect, and its track record in people who already have epilepsy is better than most clinicians expected a generation ago. Untreated depression, meanwhile, carries its own serious neurological and medical consequences, a reality that should figure into any risk-benefit conversation about starting or continuing sertraline.